Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Fibrocartilaginous Mesenchymoma of the Spine: A Case Report.
JBJS Case Connect
July 2024
Department of Orthopaedic Surgery, Washington University in St. Louis School of Medicine, St. Louis, Missouri.
Article Synopsis
- - A 19-year-old woman was found to have a large tumor at the T11 spine, identified as fibrocartilaginous mesenchymoma (FCM) after a biopsy, despite having no neurological symptoms.
- - She underwent surgical treatment that involved removing most of her spine vertebra (subtotal corpectomy) and a fusion from T8 to L1 using a cage and allograft strut.
- - FCM is a rare, locally aggressive tumor that primarily affects young adults and requires complete removal to prevent recurrence; this case marks only the sixth known instance.
Differential diagnosis of primary mesenchymal neoplasms of the breast.
Clin Transl Oncol
January 2025
Department of General Surgery, Faculty of Medicine, Uludag University, Bursa, Turkey.
Article Synopsis
- The study focuses on the rare occurrence of primary mesenchymal breast tumors, which are less common than epithelial tumors, aiming to detail their histomorphological and clinicoradiological characteristics.
- Out of 26 cases studied between 2010 and 2023, over half were benign (like hemangiomas and lipomas), while nearly half were malignant, with findings like angiosarcoma being observed.
- The conclusion emphasizes that primary breast sarcomas are very rare and recommend thorough sampling and examination of clinical and radiological data to rule out phyllodes tumors or metastasis when identifying mesenchymal tumors.
Phosphaturic mesenchymal tumor: Clinicopathological features with outcomes in 10 patients with review of literature.
Indian J Pathol Microbiol
April 2024
Department of Pathology, Tata Memorial Hospital, HBNI University, Mumbai, Maharashtra, India.
Background: Phosphaturic mesenchymal tumors (PMTs) are rare mesenchymal tumors, associated with long-standing, non-specific but often debilitating symptoms in the affected patients. These tumors display characteristic histopathological features and in case, identified timely, can be a boon for patients, given an excision is completely curative.
Aims: To evaluate the clinical and histopathological features of 10 PMTs, diagnosed at our institution, along with clinical outcomes in those patients.
A 50-Year-Old Man Presenting with Multiple Bone Lesions and a Diagnosis of Phosphaturic Mesenchymal Tumor of the Femur.
Am J Case Rep
February 2024
Department of Pathology, University of California Irvine Medical Center, Orange, CA, USA.
BACKGROUND Phosphaturic mesenchymal tumor (PMT) is an extremely rare mesenchymal neoplasm that is commonly seen in bone and soft tissue. It is associated with a paraneoplastic syndrome, oncogenic osteomalacia, due to tumor-induced urinary phosphate wasting. It is demonstrated to be predominantly mediated by fibroblast growth factor 23 (FGF23)/fibroblast growth factor receptor 1 (FGFR1) axis.
View Article and Find Full Text PDFClinical Characteristics of Malignant Phosphaturic Mesenchymal Tumor Causing Tumor-Induced Osteomalacia.
J Clin Endocrinol Metab
February 2024
Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80131 Naples, Italy.
Context: Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome usually caused by oversecretion of fibroblast growth factor 23 (FGF23) from a phosphaturic mesenchymal tumor (PMT). PMTs are usually benign neoplasms but some of them show malignant characteristics.
Objective: The aim of this study was to compare the clinical characteristics of benign and malignant PMTs inducing TIO.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!